Officials in the European Union said that a new COVID-19 variant is expected to rise across the EU in the coming weeks.
“No clinical studies are currently available for COVID-19 vaccine effectiveness for NB.1.8.1, but no significant impact on vaccine effectiveness against severe disease is anticipated based on its mutation profile and early laboratory studies,” the EU health body said on June 13.
“NB.1.8.1 is currently circulating at low proportions in the EU/EEA but is expected to rise in the coming weeks,” the statement added, referring to the European Economic Area.
It also said that “slow increases” in the virus that causes COVID-19 have been seen in the EU or EEA in recent weeks but that “levels remain low” and there has been “no significant impact on secondary care, or on the number of deaths” so far.
From May 25 to June 7 in the United States, the NB.1.8.1 variant was the second most prevalent strain by just 1 percentage point, following the LP.8.1 strain, according to a CDC update issued on June 13. A previous CDC update showed that NB.1.8.1 wasn’t being tracked in the country as of late May.
Last month, the World Health Organization deemed NB.1.8.1 a “variant under monitoring” because of its rapid spread throughout several regions, namely in parts of Asia. But it noted that the variant doesn’t appear to be causing more severe illness.
“I think their purpose of saying it is to avoid panic among the public that there will be a larger-scale outbreak this summer,” Tang said. “This wave of epidemic is still developing, and it is difficult for us to draw the conclusion that this ... has already reached its peak.”
Doctors in China, meanwhile, have told media outlets that one novel symptom related to the variant that has been reported so far is a sharp, sore throat.







